Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Accretion Pharmaceuticals IPO
Price Band
₹96.0–101.0
Issue Size
₹29.75 Cr
Lot Size
1,200 shares
Min Investment
₹121,200
GMP
—
Issue Price
₹101.0
Accretion Pharmaceuticals IPO AI Summary
- Accretion Pharmaceuticals IPO is listed on NSE SME.
- Price band: ₹96.0–₹101.0 per share, lot size 1,200 shares (min. investment ₹121,200).
- Subscription window: 14 May–16 May 2025, listing on 21 May 2025.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Accretion Pharmaceuticals IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 16 May 2025 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Accretion Pharmaceuticals IPO Grey Market Premium (GMP) Today
GMP not available yet
Grey Market Premium is updated daily. Check back closer to the listing date.
About the Company
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products. The company also offers contract manufacturing services. The Company manufactures and markets Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup). The company also holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications, reflecting its dedication to quality and environmental management systems. The company's manufacturing unit is located in Ahmedabad, Sanand, Gujarat. The company has expanded its global footprint, marking its presence in more than 20 countries, including regions in Africa, Southeast Asia, and the Middle East. Product Portfolio and Services Tablets and Capsules – Covering antibiotics, anti-inflammatory, pain management, cardiovascular, and gastrointestinal medicines. Oral Liquids and Syrups – Used for respiratory, pediatric, and digestive treatments. External Preparations – Including medicated lotions, gels, ointments, and dusting powders for skin care and dermatological treatments. Ayurvedic and Herbal Products – Focused on natural wellness solutions for immunity, digestion, and general health. As of January 2025, the company has 83 employees (including 4 Executive Directors) on its payroll. Competitive Strength: Experienced Promoters and Management Team. Long-standing relationship with clients and suppliers. Focus on providing quality products. Management has built a supply chain and customer relations, creating goodwill and trust.
Company Financials (₹ Cr)
As of 2024-12-31
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 39.99 | 27.05 | 20.58 | 17.74 |
| Total Income | 35.75 | 33.94 | 29.53 | 22.58 |
| Profit After Tax | 5.24 | 3.88 | 0.10 | 0.08 |
| NET Worth | 13.58 | 5.35 | 3.84 | 3.08 |
| Reserves and Surplus | 5.41 | 1.35 | ||
| Total Borrowing | 13.79 | 13.48 | 8.47 | 7.61 |
Key Ratios
EPS
₹4.74
NAV
₹13.37
ROE
72.47%
ROCE
36.73%
RoNW
72.47%
P/B Value
7.55
P/E Ratio
21.29
Market Cap
₹112.27 Cr
PAT Margin
11.51%
Debt/Equity
2.52
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Sotac Pharmaceuticals Limited | 43.69 | 11.91% | 23.85 | 5.24 | 5.24 |
| Lincoln Pharmaceuticals Ltd. | 295.98 | 15.74% | 12.3 | 46.58 | 46.58 |
| Sakar Healthcare Limited | 120.65 | 4.45% | 48.89 | 5.64 | 5.64 |
| Accretion Pharmaceuticals Limited This IPO | 17.09 | 38.54% | 11.56 | 8.74 | 8.74 |
Promoters
Mayur Popatlal Sojitra, Harshad Nanubhai Rathod, Vivek Ashok Kumar Patel and Hardik Mukundbhai Prajapati
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Capital expenditure towards purchase of new equipment/ machineries, etc. 2.70 2 Capital expenditure towards upgradation of existing manufacturing facility 4.66 3 Repayment/prepayme nt of certain borrowings availed by the Company 0.99 4 Funding working capital requirements of the Company 14.68 5 General Corporate Purposes 4.43 6 Issue Expenses 2.30 Total 29.75
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Revenue was ₹22.58 Cr in the year ending 31 Mar 2022, increasing to ₹29.53 Cr by 31 Mar 2023, and further rising to ₹33.94 Cr by 31 Mar 2024. The most recent figure for total income was ₹35.75 Cr as of 31 Dec 2024.
Profit Trend
Profit After Tax was ₹0.08 Cr in the year ending 31 Mar 2022, which rose to ₹0.10 Cr by 31 Mar 2023. This further increased to ₹3.88 Cr by 31 Mar 2024, and reached ₹5.24 Cr as of 31 Dec 2024.
Valuation
Accretion Pharmaceuticals Limited has an implied P/E ratio of 11.56 at the issue price, compared to peers trading at a P/E range of 12.3 to 48.89.
Grey Market Premium, Explained
The grey market refers to the unofficial market where shares are traded before they are listed on the stock exchange. The Grey Market Premium (GMP) indicates the expected listing price of an IPO based on current demand in this unofficial market. A higher GMP suggests strong demand, while a lower GMP may indicate weaker interest.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment goals and risk tolerance. It's important to consider the company's growth potential and market conditions.
Who May Want to Wait
Investors who prefer stable and established companies with predictable earnings may want to avoid IPOs like this, which can be more volatile and less predictable.
Listing Gains — The Risk
Listing-day gains can be unpredictable and depend on various factors, including market sentiment and demand for the stock. Investors should be aware that there is a risk of losing money if the stock does not perform well on its first day of trading.
This evaluation is generated from Accretion Pharmaceuticals's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is the price band of Accretion Pharmaceuticals IPO?
The price band of Accretion Pharmaceuticals IPO is ₹96.0–₹101.0 per share.
When does Accretion Pharmaceuticals IPO open and close?
Accretion Pharmaceuticals IPO opens on 14 May 2025 and closes on 16 May 2025.
When does Accretion Pharmaceuticals IPO list on the stock exchange?
Accretion Pharmaceuticals IPO listed on 21 May 2025 at ₹101.0.
What is the lot size for Accretion Pharmaceuticals IPO?
The lot size for Accretion Pharmaceuticals IPO is 1200 shares, requiring a minimum investment of ₹121,200.
What is the price band for the IPO?
The price band for the IPO is ₹96.0 to ₹101.0.
What is the minimum investment required?
The minimum investment required is ₹121,200.
What is the lot size for the IPO?
The lot size for the IPO is 1,200 shares.
When does the IPO open and close?
The IPO opens on May 14, 2025, and closes on May 16, 2025.
When is the listing date?
The listing date is May 21, 2025.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
14 May 2025
Close
16 May 2025
Allotment
19 May 2025
Listing
21 May 2025
Similar IPOs
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Accretion Pharmaceuticals?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.